Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...

Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the ...

Politics and elections have the potential to upend near-term carbon abatement targets and ESG strategies, so what's on the ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other biopharma firms. Aside from JPM conference coverage, our reporters are making their way around town for one-on ...

AbbVie bought the rights to SIM0500, a trispecific T-cell engager for multiple myeloma, from Chinese pharmaceutical company Simcere Zaiming for an undisclosed upfront payment and up to $1.05 billion ...

India lost the fifth Test against Australia in Sydney, resulting in a 3-1 series defeat. With that, India also missed the World Test Championship final qualification. Yashasvi Jaiswal stood out ...